1. De la Fuente-García A, Ocampo-Candiani J. melanoma cutáneo. Gac Méd Méx Vol. 146 No. 2, 2010. 2. Rademaker M. new Zeland guidelines on the general management of malignant melanoma. 2004. 3. Royal College of Physicians and British association of dermatologist. The prevention, diagnosis, referral and management of melanoma of the skin: concise guidance to good practice series, no. 7. London RCP 2007. 4. Meyskens FL. Management of human melanoma. What has the last decade wrought? The Oncologist 2003;8: 448-450 5. Rivers J. Worldwide melanoma Update 2000. Vol II Skin Cancer Foundation 6. Armstrong BK, Kricker A, How much melanoma is caused by sun exposure? Melanoma Res 1993. 3: 395-401 7. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA, Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium J Clin Oncol 1999;17(10): 3245-51 8. Clemente A. Protocolo de manejo de pacientes con melanoma cutáneo. Servicio de Dermatología. Hospital Clínico San Cecilio. Granada. Premio al mejor protocolo. Septiembre 2006. 9. De Balch CM. Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DB y col. Final versión of the American Joint comité on Cancer Staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48. 10. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003;21(1):43-52. 11. Markowitz JS, Cosimi LA, Carey RW, Kang S, Padyk C, Sober AJ, et al. Prognosis after initial recurrence of cutaneous melanoma. Arch Surg. 1991;126:703-8. 12. Tejera A, Barrera MV, Fernández I, Blázquez N, Mendiola M, Fernández A, Bosch R, de troya M, Herrera E. Estudio temporal de los diferentes patrones metastásicos en la progresión del melanoma cutáneo. Actas Dermosifiliogr 2007;98:531-8. 13. Charles M. Balch Final Version of 2009 AJCC Melanoma Staging and Classification J Clin Oncol 2009, 27:6199-6206 14. Manejo del melanoma metastásico. León E, Aguilar JL, Figueroa J, Barra R, Beltrán A, Martínez H, et. al. 1er. Consenso Nacional de Expertos en Melanoma del Capítulo de Tumores de Piel y Melanoma de la Sociedad Mexicana de Oncología y la Clínica de Melanoma del Instituto Nacional de Cancerología. Vol. 4 Suplemento 2, 2005. 15. Jeffrey E. Gershenwald, Seng-jaw Soong, Charles M. Balch. 2010 TNM Staging System for Cutaneous Melanoma…and Beyond. Annals of Surgical Oncology. Volume 17, Number 6, 1475-1477, DOI: 10.1245/s10434-010-0986-3. 16. Cancer. Principles and Practice of Oncology .Capitulo 38. Melanoma. Eds: De Vita V, Hellman S, Rosenberg S. Londres- New York 8ma edición 2008. 17. Garrido MC, Rodríguez JL. Factores pronósticos del melanoma. Revisiones en cáncer, ISSN 0213-8573, Vol.21, No.4, 2007. (Ejemplar dedicado a: Melanoma) , pags. 162-169. 18. Bedikian AY, Johnson MM, Warneke CL, et al. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma. Cancer Invest 2008;26:624-33. 19. Vazquez V, Otero L, Laurent V, Gabri M, Gomez D, Alonso D. detección molecular de enfermedad mínima residual en melanoma y otros tumores sólidos. Medicina (Buenos Aires) 2009; 69: 181-190 20. Agarwala SS. Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther 2009;9:587-95. 21. Eggermont AM, Kirkwood JM. Reevaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40:1825-36. 22. Trinh VA. Current management of metastatic melanoma. Am J Health Syst Pharm 2008;65:Suppl 9:S3-S8. 23. Duarte C, Melo M, Venegas M. Perfusión aislada de extremidades. Rev Colomb Cancerol 2008;12(4):213-218 24. Melero I, Hervas-Stubbs S, Glennie M, Pardoll DM, Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007;7:95-106. 25. O’Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 2007;110:2614-27. 26. Kirkwood J, Ibrahim J, Sondak V, Richards J, Flaherty L, Ernstoff M, et al. High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/ C9190. Journal of Clinical Oncology, Vol 18, No 12 (June), 2000: pp 2444-2458 27. Kirkwood J, Manola J, Ibrahim J, Sondak V, Ernstoff M, Rao U. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma. Clinical Cancer Research Vol. 10, 1670–1677. 2004 28. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clinical Cancer Research, 2008, 14(17):5610-8 29. Rosenberg SA. Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am 6(suppl 1):s2-7 (2000 Feb). 30. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 6(suppl 1):s11-4 (2000 Feb). 31. Atkins MB. Interleukin-2 in metastatic melanoma: what is the current role? Cancer J Sci Am 6(suppl 1):s8-10 (2000 Feb). 32. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4(3):321-7 (1998 Mar). 33. Nestle FO,Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4(3):328-32 (1998 Mar). 34. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician’s choice of treatment for stage IV melanoma. J Clin Oncol 2008;26:955-62. 35. Roque-Navarro L, Chakrabandhu K, de León J, Rodríguez S, Toledo C, Carr A, Mateo de Acosta C, Hueber AO, Pérez R. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 2008;7(7). 36. Mulens V, Marinello P, Carr A, Mazorra Z, Fernández LE. Gangliósidos en la Biología e Inmunoterapia del Cáncer: la Experiencia Cubana. Cancerología 4 (2009): 155-167 37. Wiegandt H: The chemical structures of gangliosides. En: Oettgen HF, Ed.. Gangliosides and cancer, VCH Pubkishers, New York, 1989. 38. Marquina G, Waki H, Fernandez LE, Kon K, Carr A, Valiente O et al. Gangliosides expressed in human breast cancer. Cancer Res 56: 5165-5171, 1996. 39. Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. J Natl Cancer Inst 78:45, 1987. 40. Maguire HC Jr. Vaccine therapy in the treatment of melanoma. Int J Dermatol 32(4):259-260, 1993. 41. Hamilton WB et al. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromathography. Int J Cancer 53(4)::566-573, 1993. 42. Helling F, Livington PO. Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origen. Mol Chem Neurophathol 21:299-309, 1994. 43. Carr A, Mullet A, Mazorra Z, Vázquez AM, Alfonso M, Mesa C, Rengifo E, Pérez R and Fernández LE. A mouse IgG1 Monoclonal Antibody Specific for N-Glycolyl GM3 Ganglioside recognized Breast and Melanoma Tumors. Hybridoma 19(3): 241-247, 2000 44. Mauro A., Díaz A, Hernández AM, Pérez A, Rodríguez E, Bitton R, Pérez R, Vázquez AM. An Anti-Idiotype vaccine Elicts a Specific response to N-Glycoliyl Acid residues of Glycoconjugates in Melanoma Patients.The Journal Immunolgy 168:2523- 2559, 2002. 45. Nakarai H, Chandler PJ, Kano K, Morton Dl, Irie Rf. Hanganutziu-Deicher antigen as a possible target for inmotherapy of melanoma. Int Arch Allergy Appl Immunol 91(3): 323-328, 1990. 46. Saida T, Ikegawa S, Takizawa Y, Kawachi S. Immunohistochemical detection of heterophile Hanganutziu-Deicher antigen in human malignant melanoma. Arch Dermatol Res 282(3):179-182, 1990. 47. Kawachi S, Saida T. Analysis of th expression of Hanganutziu-Decher (HD) antigen in human malignant melanoma. J Dermatol 19(11):827-830, 1992. 48. Takahashi T, Johnson TD, Nishinaka Y, Morton DL, Irie RF. IgManti-ganglioside antibodies induced by melanoma cell vaccine correlate with survival of melanoam patients. J Invest Dermatol, 112 (2):205-209, 1999. 49. Dore JF et al. Response in patients with melanoma to immunization using melanoma oncolysates of vaccine virus. Bull Cancer 77(9):881-891, 1990. 50. Nakarai H, Chandler PJ, Kano K, Morton DL, Irie RF. Hanganutziu-Deicher antigen as a possible target for immunotherapy of melanoma. Int Arch Allergy Appl Immunol 91(3):323-328, 1990. 51. Livingston PO. Immunotherapy of Melanoma and Colon Cancer with Purified Carbohydrates Vaccines. Proc Am Assoc Cancer Res 32: 491-492: 1991. 52. Helling F, Shang A, Calves M, Zhang S, Ren S, Yu RK, Oettgen HF, Livingston, PO. GD3 Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin (KLH) Conjugate Vaccines. Cancer Res 54: 197-203; 1994. 53. Livingston, PO. Ganglioside Vaccine with Emphasis on GM2. Semin Oncol. 25(6):636-645, 1998.